Shanxi C&Y Pharmaceutical Group Co Ltd (300254) - Total Liabilities
Based on the latest financial reports, Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has total liabilities worth CN¥972.67 Million CNY (≈ $142.33 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Shanxi C&Y Pharmaceutical Group Co Ltd to assess how effectively this company generates cash.
Shanxi C&Y Pharmaceutical Group Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Shanxi C&Y Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 300254 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Shanxi C&Y Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanxi C&Y Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alexander Forbes Grp Hldg Ltd
JSE:AFH
|
South Africa | ZAC465.55 Billion |
|
Shenzhen Liantronics
SHE:300269
|
China | CN¥643.66 Million |
|
Dada Nexus Ltd
NASDAQ:DADA
|
USA | $1.61 Billion |
|
Fenix Outdoor International AG
ST:FOI-B
|
Sweden | Skr344.80 Million |
|
Ningbo Tianyi Medical Appliance Co. Ltd.
SHE:301097
|
China | CN¥719.16 Million |
|
ScinoPharm Taiwan Ltd
TW:1789
|
Taiwan | NT$1.33 Billion |
|
Yulon Nissan Motor Co Ltd
TW:2227
|
Taiwan | NT$4.74 Billion |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
Korea | ₩209.82 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Shanxi C&Y Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300254 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanxi C&Y Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual total liabilities of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥949.55 Million ≈ $138.95 Million |
+45.05% |
| 2023-12-31 | CN¥654.64 Million ≈ $95.79 Million |
-23.40% |
| 2022-12-31 | CN¥854.64 Million ≈ $125.06 Million |
+9.26% |
| 2021-12-31 | CN¥782.23 Million ≈ $114.46 Million |
-15.70% |
| 2020-12-31 | CN¥927.91 Million ≈ $135.78 Million |
+6.73% |
| 2019-12-31 | CN¥869.43 Million ≈ $127.22 Million |
+54.03% |
| 2018-12-31 | CN¥564.47 Million ≈ $82.60 Million |
+3.11% |
| 2017-12-31 | CN¥547.42 Million ≈ $80.10 Million |
+14.59% |
| 2016-12-31 | CN¥477.74 Million ≈ $69.91 Million |
+9.59% |
| 2015-12-31 | CN¥435.93 Million ≈ $63.79 Million |
+21.71% |
| 2014-12-31 | CN¥358.17 Million ≈ $52.41 Million |
+10.82% |
| 2013-12-31 | CN¥323.21 Million ≈ $47.30 Million |
+83.65% |
| 2012-12-31 | CN¥175.99 Million ≈ $25.75 Million |
+44.98% |
| 2011-12-31 | CN¥121.39 Million ≈ $17.76 Million |
-7.51% |
| 2010-12-31 | CN¥131.25 Million ≈ $19.21 Million |
-7.51% |
| 2009-12-31 | CN¥141.91 Million ≈ $20.77 Million |
+20.82% |
| 2008-12-31 | CN¥117.45 Million ≈ $17.19 Million |
-- |
About Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, comme… Read more